Identification of a seven glycopeptide signature for malignant pleural mesothelioma in human serum by selected reaction monitoring
详细信息 查看全文
- 作者：Ferdinando Cerciello (10) (11)
Meena Choi (12)
Annalisa Nicastri (10)
Damaris Bausch-Fluck (10) (11) (11)
Annemarie Ziegler (11) (12)
Olga Vitek (12) (12)
Emanuela Felley-Bosco (11)
Rolf Stahel (11)
Ruedi Aebersold (10) (10)
Bernd Wollscheid (10) (11) (11) - 关键词：Malignant pleural mesothelioma ; Selected reaction monitoring ; Surfaceome ; Targeted proteomics ; Serum biomarkers
- 刊名：Clinical Proteomics
- 出版年：2013
- 出版时间：December 2013
- 年：2013
- 卷：10
- 期：1
- 全文大小：624 KB
- 参考文献：1. Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, Corson JM, DeCamp MM Jr, Swanson SJ, Bueno R, Lukanich JM, / et al.: Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. / J Thorac Cardiovasc Surg 1999, 117:54-3. discussion 63-5 CrossRef
2. Weder W, Kestenholz P, Taverna C, Bodis S, Lardinois D, Jerman M, Stahel RA: Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. / J Clin Oncol 2004, 22:3451-457. CrossRef
3. Flores RM, Krug LM, Rosenzweig KE, Venkatraman E, Vincent A, Heelan R, Akhurst T, Rusch VW: Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial. / J Thorac Oncol 2006, 1:289-95. CrossRef
4. Weder W, Stahel RA, Bernhard J, Bodis S, Vogt P, Ballabeni P, Lardinois D, Betticher D, Schmid R, Stupp R, / et al.: Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. / Ann Oncol 2007, 18:1196-202. CrossRef
5. Krug LM, Pass HI, Rusch VW, Kindler HL, Sugarbaker DJ, Rosenzweig KE, Flores R, Friedberg JS, Pisters K, Monberg M, / et al.: Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. / J Clin Oncol 2009, 27:3007-013. CrossRef
6. Wilcox BE, Subramaniam RM, Peller PJ, Aughenbaugh GL, Nichols Iii FC, Aubry MC, Jett JR: Utility of integrated computed tomography-positron emission tomography for selection of operable malignant pleural mesothelioma. / Clin Lung Cancer 2009, 10:244-48. CrossRef
7. Sorensen JB, Ravn J, Loft A, Brenoe J, Berthelsen AK: Preoperative staging of mesothelioma by 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography fused imaging and mediastinoscopy compared to pathological findings after extrapleural pneumonectomy. / Eur J Cardiothorac Surg 2008, 34:1090-096. CrossRef
8. de Perrot M, Feld R, Cho BC, Bezjak A, Anraku M, Burkes R, Roberts H, Tsao MS, Leighl N, Keshavjee S, Johnston MR: Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. / J Clin Oncol 2009, 27:1413-418. CrossRef
9. Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, Winzell P, Hellstrom KE, Hellstrom I: Mesothelin-family proteins and diagnosis of mesothelioma. / Lancet 2003, 362:1612-616. CrossRef
10. Hollevoet K, Reitsma JB, Creaney J, Grigoriu BD, Robinson BW, Scherpereel A, Cristaudo A, Pass HI, Nackaerts K, Rodriguez Portal JA, / et al.: Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. / J Clin Oncol 2012, 30:1541-549. CrossRef
11. Pass HI, Levin SM, Harbut MR, Melamed J, Chiriboga L, Donington J, Huflejt M, Carbone M, Chia D, Goodglick L, / et al.: Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. / N Engl J Med 2012, 367:1417-427. CrossRef
12. Fu Q, Schoenhoff FS, Savage WJ, Zhang P, Van Eyk JE: Multiplex assays for biomarker research and clinical application: translational science coming of age. / Proteomics Clin Appl 2010, 4:271-84. CrossRef
13. Picotti P, Bodenmiller B, Aebersold R: Proteomics meets the scientific method. / Nat Methods 2013, 10:24-7. CrossRef
14. Lange V, Picotti P, Domon B, Aebersold R: Selected reaction monitoring for quantitative proteomics: a tutorial. / Mol Syst Biol 2008, 4:222. CrossRef
15. Addona TA, Abbatiello SE, Schilling B, Skates SJ, Mani DR, Bunk DM, Spiegelman CH, Zimmerman LJ, Ham AJ, Keshishian H, / et al.: Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. / Nat Biotechnol 2009, 27:633-41. CrossRef
16. Elschenbroich S, Ignatchenko V, Clarke B, Kalloger S, Boutros P, Gramolini A, Shaw P, Jurisica I, Kislinger T: In-depth proteomics of ovarian cancer ascites: combining shotgun proteomics and selected reaction monitoring mass spectrometry. / J Proteome Res 2011, 10:2286-299. CrossRef
17. Whiteaker JR, Lin C, Kennedy J, Hou L, Trute M, Sokal I, Yan P, Schoenherr RM, Zhao L, Voytovich UJ, / et al.: A targeted proteomics-based pipeline for verification of biomarkers in plasma. / Nat Biotechnol 2011, 29:625-34. CrossRef
18. Ziegler A, Cerciello F, Bigosch C, Bausch-Fluck D, Felley-Bosco E, Ossola R, Soltermann A, Stahel RA, Wollscheid B: Proteomic surfaceome analysis of mesothelioma. / Lung Cancer 2012, 75:189-96. CrossRef
19. Anderson NL, Anderson NG: The human plasma proteome: history, character, and diagnostic prospects. / Mol Cell Proteomics 2002, 1:845-67. CrossRef
20. Zhang H, Li XJ, Martin DB, Aebersold R: Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. / Nat Biotechnol 2003, 21:660-66. CrossRef
21. Tian Y, Zhou Y, Elliott S, Aebersold R, Zhang H: Solid-phase extraction of N-linked glycopeptides. / Nat Protoc 2007, 2:334-39. CrossRef
22. Zhou Y, Aebersold R, Zhang H: Isolation of N-linked glycopeptides from plasma. / Anal Chem 2007, 79:5826-837. CrossRef
23. Stahl-Zeng J, Lange V, Ossola R, Eckhardt K, Krek W, Aebersold R, Domon B: High sensitivity detection of plasma proteins by multiple reaction monitoring of N-glycosites. / Mol Cell Proteomics 2007, 6:1809-817. CrossRef
24. Picotti P, Rinner O, Stallmach R, Dautel F, Farrah T, Domon B, Wenschuh H, Aebersold R: High-throughput generation of selected reaction-monitoring assays for proteins and proteomes. / Nat Methods 2010, 7:43-6. CrossRef
25. Chang K, Pastan I: Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. / Proc Natl Acad Sci U S A 1996, 93:136-40. CrossRef
26. Hellstrom I, Raycraft J, Kanan S, Sardesai NY, Verch T, Yang Y, Hellstrom KE: Mesothelin variant 1 is released from tumor cells as a diagnostic marker. / Cancer Epidemiol Biomarkers Prev 2006, 15:1014-020. CrossRef
27. Ho M, Onda M, Wang QC, Hassan R, Pastan I, Lively MO: Mesothelin is shed from tumor cells. / Cancer Epidemiol Biomarkers Prev 2006, 15:1751. CrossRef
28. Beyer HL, Geschwindt RD, Glover CL, Tran L, Hellstrom I, Hellstrom KE, Miller MC, Verch T, Allard WJ, Pass HI, Sardesai NY: MESOMARK: a potential test for malignant pleural mesothelioma. / Clin Chem 2007, 53:666-72. CrossRef
29. Scholler N, Fu N, Yang Y, Ye Z, Goodman GE, Hellstrom KE, Hellstrom I: Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. / Proc Natl Acad Sci U S A 1999, 96:11531-1536. CrossRef
30. Wollscheid B, Bausch-Fluck D, Henderson C, O’Brien R, Bibel M, Schiess R, Aebersold R, Watts JD: Mass-spectrometric identification and relative quantification of N-linked cell surface glycoproteins. / Nat Biotechnol 2009, 27:378-86. CrossRef
31. de Graaf E, Altelaar A, van Breukelen B, Mohammed S, Heck A: Improving SRM assay development: a global comparison between triple quadrupole, ion trap, and higher energy CID peptide fragmentation spectra. / J Proteome Res 2011, 10:4334-341. CrossRef
32. Farrah T, Deutsch EW, Omenn GS, Campbell DS, Sun Z, Bletz JA, Mallick P, Katz JE, Malmstrom J, Ossola R, / et al.: A high-confidence human plasma proteome reference set with estimated concentrations in PeptideAtlas. / Mol Cell Proteomics 2012, 10:M110 006353.
33. Pass HI, Lott D, Lonardo F, Harbut M, Liu Z, Tang N, Carbone M, Webb C, Wali A: Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. / N Engl J Med 2005, 353:1564-573. CrossRef
34. Grigoriu B, Chahine B, Zerimech F, Gregoire M, Balduyck M, Copin MC, Devos P, Lassalle P, Scherpereel A: Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma. / Clin Biochem 2009, 42:1046-050. CrossRef
35. Hollevoet K, Nackaerts K, Thimpont J, Germonpre P, Bosquee L, De Vuyst P, Legrand C, Kellen E, Kishi Y, Delanghe JR, van Meerbeeck JP: Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma. / Am J Respir Crit Care Med 2010, 181:620-25. CrossRef
36. Schouwink H, Korse CM, Bonfrer JM, Hart AA, Baas P: Prognostic value of the serum tumour markers Cyfra 21- and tissue polypeptide antigen in malignant mesothelioma. / Lung Cancer 1999, 25:25-2. CrossRef
37. Chang CY, Picotti P, Hüttenhain R, Heinzelmann-Schwarz V, Jovanovic M, Aebersold R, Vitek O: Protein significance analysis in selected reaction monitoring (SRM) measurements. / Mol Cell Proteomics 2012, 11:M111 014662.
38. Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, Winget M, Yasui Y: Phases of biomarker development for early detection of cancer. / J Natl Cancer Inst 2001, 93:1054-061. CrossRef
39. Zhang Z, Chan DW: The road from discovery to clinical diagnostics: lessons learned from the first FDA-cleared in vitro diagnostic multivariate index assay of proteomic biomarkers. / Cancer Epidemiol Biomarkers Prev 2010, 19:2995-999. CrossRef
40. Elschenbroich S, Kislinger T: Targeted proteomics by selected reaction monitoring mass spectrometry: applications to systems biology and biomarker discovery. / Mol Biosyst 2011, 7:292-03. CrossRef
41. Rifai N, Gillette MA, Carr SA: Protein biomarker discovery and validation: the long and uncertain path to clinical utility. / Nat Biotechnol 2006, 24:971-83. CrossRef
42. Roth J, Zuber C, Park S, Jang I, Lee Y, Kysela K, Fourn VL, Santimaria R, Guhl B, Cho J: Protein N-glycosylation, protein folding, and protein quality control. / Mol Cells 2010, 30:497-06. CrossRef
43. Zhang H, Liu AY, Loriaux P, Wollscheid B, Zhou Y, Watts JD, Aebersold R: Mass spectrometric detection of tissue proteins in plasma. / Mol Cell Proteomics 2007, 6:64-1. CrossRef
44. Fusaro VA, Mani DR, Mesirov JP, Carr SA: Prediction of high-responding peptides for targeted protein assays by mass spectrometry. / Nat Biotechnol 2009, 27:190-98. CrossRef
45. Duncan MW, Aebersold R, Caprioli RM: The pros and cons of peptide-centric proteomics. / Nat Biotechnol 2010, 28:659-64. CrossRef
46. Fang Q, Kani K, Faca VM, Zhang W, Zhang Q, Jain A, Hanash S, Agus DB, McIntosh MW, Mallick P: Impact of protein stability, cellular localization, and abundance on proteomic detection of tumor-derived proteins in plasma. / PLoS One 2011, 6:e23090. CrossRef
47. Wang J, Willumsen N, Zheng Q, Xue Y, Karsdal MA, Bay-Jensen AC: Bringing cancer serological diagnosis to a new level: focusing on HER2, protein ectodomain shedding and neoepitope technology. / Future Oncol 2013, 9:35-4. CrossRef
48. Craig SE, Brady-Kalnay SM: Cancer cells cut homophilic cell adhesion molecules and run. / Cancer Res 2011, 71:303-09. CrossRef
49. Mason SD, Joyce JA: Proteolytic networks in cancer. / Trends Cell Biol 2011, 21:228-37. CrossRef
50. Wilken JA, Perez-Torres M, Nieves-Alicea R, Cora EM, Christensen TA, Baron AT, Maihle NJ: Shedding of soluble epidermal growth factor receptor (sEGFR) is mediated by a metalloprotease/fibronectin/integrin axis and inhibited by cetuximab. / Biochemistry 2013, 52:4531-540. CrossRef
51. Ebos JM, Bocci G, Man S, Thorpe PE, Hicklin DJ, Zhou D, Jia X, Kerbel RS: A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma. / Mol Cancer Res 2004, 2:315-26.
52. Shah N, Cabanillas F, McIntyre B, Feng L, McLaughlin P, Rodriguez MA, Romaguera J, Younes A, Hagemeister FB, Kwak L, Fayad L: Prognostic value of serum CD44, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 levels in patients with indolent non-Hodgkin lymphomas. / Leuk Lymphoma 2012, 53:50-6. CrossRef
53. Iozzo RV, Sanderson RD: Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. / J Cell Mol Med 2011, 15:1013-031. CrossRef
54. Nanda A, Carson-Walter EB, Seaman S, Barber TD, Stampfl J, Singh S, Vogelstein B, Kinzler KW, Croix BS: TEM8 Interacts with the cleaved C5 domain of collagen α3(VI). / Cancer Res 2004, 64:817-20. CrossRef
55. Miyagi T, Hori O, Koshida K, Egawa M, Kato H, Kitagawa Y, Ozawa K, Ogawa S, Namiki M: Antitumor effect of reduction of 150-kDa oxygen-regulated protein expression on human prostate cancer cells. / Int J Urol 2002, 9:577-85. CrossRef
56. Isenberg JS, Martin-Manso G, Maxhimer JB, Roberts DD: Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies. / Nat Rev Cancer 2009, 9:182-94. CrossRef
57. Easton DP, Kaneko Y, Subjeck JR: The Hsp110 and Grp170 stress proteins: newly recognized relatives of the Hsp70s. / Cell Stress Chaperones 2000, 5:276-90. CrossRef
58. Naaby-Hansen S, Herr JC: Heat shock proteins on the human sperm surface. / J Reprod Immunol 2010, 84:32-0. CrossRef
59. Calvert ME, Digilio LC, Herr JC, Coonrod SA: Oolemmal proteomics -identification of highly abundant heat shock proteins and molecular chaperones in the mature mouse egg and their localization on the plasma membrane. / Reprod Biol Endocrinol 2003, 1:27-7. CrossRef
60. Beachy SH, Kisailus AJ, Repasky EA, Subjeck JR, Wang XY, Kazim AL: Engineering secretable forms of chaperones for immune modulation and vaccine development. / Methods 2007, 43:184-93. CrossRef
61. Altmeyer A, Maki R, Feldweg A, Heike M, Protopopov V, Masur S, Srivastava P: Tumor-specific cell surface expression of the-KDEL containing, endoplasmic reticular heat shock protein gp96. / Int J Cancer 1996, 69:340-49. CrossRef
62. Gastpar R, Gross C, Rossbacher L, Ellwart J, Riegger J, Multhoff G: The cell surface-localized heat shock protein 70 epitope TKD induces migration and cytolytic activity selectively in human NK cells. / J Immunol 2004, 172:972-80.
63. Vega VL, Rodr?’guez-Silva M, Frey T, Gehrmann M, Diaz JC, Steinem C, Multhoff G, Arispe N, Maio AD: Hsp70 Translocates into the plasma membrane after stress and is released into the extracellular environment in a membrane-associated form that activates macrophages. / J Immunol 2008, 180:4299-307.
64. Hüttenhain R, Soste M, Selevsek N, R?st H, Sethi A, Carapito C, Farrah T, Deutsch EW, Kusebauch U, Moritz RL, / et al.: Reproducible quantification of cancer-associated proteins in body fluids using targeted proteomics. / Sci Transl Med 2012, 4:142ra194. CrossRef
65. / The SRMAtlas. http://www.srmatlas.org
66. Thurneysen C, Opitz I, Kurtz S, Weder W, Stahel RA, Felley-Bosco E: Functional inactivation of NF2/merlin in human mesothelioma. / Lung Cancer 2009, 64:140-47. CrossRef
67. Knobel PA, Kotov IN, Felley-Bosco E, Stahel RA, Marti TM: Inhibition of REV3 expression induces persistent DNA damage and growth arrest in cancer cells. / Neoplasia 2011, 13:961-70.
68. Pedrioli PG, Eng JK, Hubley R, Vogelzang M, Deutsch EW, Raught B, Pratt B, Nilsson E, Angeletti RH, Apweiler R, / et al.: A common open representation of mass spectrometry data and its application to proteomics research. / Nat Biotechnol 2004, 22:1459-466. CrossRef
69. Mueller LN, Rinner O, Schmidt A, Letarte S, Bodenmiller B, Brusniak MY, Vitek O, Aebersold R, Müller M: SuperHirn - a novel tool for high resolution LC-MS-based peptide/protein profiling. / Proteomics 2007, 7:3470-480. CrossRef
70. Eng JK, McCormack AL, Yates JR: An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database. / J Am Soc Mass Spectrom 1994, 5:976-89. CrossRef
71. / The UniProt Knowledgebase. (UniProtKB) http://www.uniprot.org
72. / Blood Transfusion Service Zürich, SRC, Switzerland. http://www.zhbsd.ch
73. MacLean B, Tomazela DM, Shulman N, Chambers M, Finney GL, Frewen B, Kern R, Tabb DL, Liebler DC, MacCoss MJ: Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. / Bioinformatics 2010, 26:966-68. CrossRef
74. Escher C, Reiter L, Maclean B, Ossola R, Herzog F, Chilton J, Maccoss MJ, Rinner O: Using iRT, a normalized retention time for more targeted measurement of peptides. / Proteomics 2012, 12:1111-121. CrossRef
75. / Laboratory for Statistical Proteomics and Bioinformatics. http://www.stat.purdue.edu/~ovitek/Home.html
76. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, Müller M: pROC: an open-source package for R and S-?to analyze and compare ROC curves. / BMC Bioinforma 2011, 12:77. CrossRef - 作者单位：Ferdinando Cerciello (10) (11)
Meena Choi (12)
Annalisa Nicastri (10)
Damaris Bausch-Fluck (10) (11) (11)
Annemarie Ziegler (11) (12)
Olga Vitek (12) (12)
Emanuela Felley-Bosco (11)
Rolf Stahel (11)
Ruedi Aebersold (10) (10)
Bernd Wollscheid (10) (11) (11)
10. Faculty of Science, University Zürich, Zürich, Switzerland
11. Department of Health Sciences and Technology, Swiss Federal Institute of Technology (ETH) Zürich, Zürich, Switzerland
12. Centro de Genética Humana, Clínica Alemana-Universidad del Desarrollo, Santiago, Chile - ISSN：1559-0275
文摘
Background Serum biomarkers can improve diagnosis and treatment of malignant pleural mesothelioma (MPM). However, the evaluation of potential new serum biomarker candidates is hampered by a lack of assay technologies for their clinical evaluation. Here we followed a hypothesis-driven targeted proteomics strategy for the identification and clinical evaluation of MPM candidate biomarkers in serum of patient cohorts. Results Based on the hypothesis that cell surface exposed glycoproteins are prone to be released from tumor-cells to the circulatory system, we screened the surfaceome of model cell lines for potential MPM candidate biomarkers. Selected Reaction Monitoring (SRM) assay technology allowed for the direct evaluation of the newly identified candidates in serum. Our evaluation of 51 candidate biomarkers in the context of a training and an independent validation set revealed a reproducible glycopeptide signature of MPM in serum which complemented the MPM biomarker mesothelin. Conclusions Our study shows that SRM assay technology enables the direct clinical evaluation of protein-derived candidate biomarker panels for which clinically reliable ELISA’s currently do not exist.